{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:01:05Z","timestamp":1792036865089,"version":"4.4.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jdcr.2025.03.028","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T03:09:22Z","timestamp":1744340962000},"page":"154-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Granuloma annulare treated with certolizumab following the development of antidrug antibodies to adalimumab"],"prefix":"10.1016","volume":"61","author":[{"given":"Ayelet I.","family":"Rubenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-7815","authenticated-orcid":false,"given":"Jina","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Rosenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jdcr.2025.03.028_bib1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2015.03.054","article-title":"Granuloma annulare: clinical and histologic variants, epidemiology, and genetics","volume":"75","author":"Piette","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2025.03.028_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jaad.2015.09.015","article-title":"Treatment of recalcitrant granuloma annulare (GA) with adalimumab: a single-center, observational study","volume":"74","author":"Min","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2025.03.028_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2023.09.050","article-title":"Results of a treatment algorithm for generalized granuloma annulare","volume":"90","author":"Berk-Krauss","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2025.03.028_bib4","article-title":"Improvement of generalized granuloma annulare with adalimumab: A case report","volume":"12","author":"Horoub","year":"2024","journal-title":"SAGE Open Med Case Rep"},{"issue":"14","key":"10.1016\/j.jdcr.2025.03.028_bib5","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jdcr.2025.03.028_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaad.2015.03.055","article-title":"Granuloma annulare: pathogenesis, disease associations and triggers, and therapeutic options","volume":"75","author":"Piette","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2025.03.028_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.808606","article-title":"Pegylation reduces the uptake of certolizumab pegol by dendritic cells and epitope presentation to T-cells","volume":"13","author":"de Bourayne","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jdcr.2025.03.028_bib8","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/ijd.14350","article-title":"The role of biologics in the treatment of chronic granuloma annulare","volume":"58","author":"Chen","year":"2019","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.jdcr.2025.03.028_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208922","article-title":"Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-alpha biologicals and an Infliximab-biosimilar","volume":"13","author":"Buurman","year":"2018","journal-title":"PLoS One"},{"issue":"10061","key":"10.1016\/j.jdcr.2025.03.028_bib10","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625001572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625001572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T19:56:10Z","timestamp":1760644570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512625001572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":10,"alternative-id":["S2352512625001572"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.03.028","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Granuloma annulare treated with certolizumab following the development of antidrug antibodies to adalimumab","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}